Plan to extend survival with an oral systemic treatment at every opportunity

Recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in HCC1

Appropriate HCC patient types (Child-Pugh class A [category 1] or B7 [category 2A])1

Unresectable because of inadequate hepatic reserve or tumor location

Inoperable because of performance status or comorbidity, local disease, or local disease with minimal extrahepatic disease only

HCC with metastatic disease or extensive liver tumor burden

National Comprehensive Cancer Network (NCCN®) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

After NEXAVAR® (sorafenib) progression, consider STIVARGA® (regorafenib) to continue your HCC treatment plan2

RESORCE helped establish a systemic treatment plan3-5

Systemic treatment plan established from RESORCE trial data.

STIVARGA is appropriate for patients with HCC who have progressed on NEXAVAR

Patients with HCC in the RESORCE trial included4:

  • Child-Pugh class A
  • ECOG performance status 0-1
  • Macrovascular invasion and/or extrahepatic disease (with or without)
  • BCLC stage B and C
  • As seen in the RESORCE study, appropriate patients must have tolerated sorafenib (≥400 mg daily) for at least 20 of the 28 days before discontinuation and received their last sorafenib dose within 10 weeks of randomization5

Regorafenib (STIVARGA) is an NCCN Guidelines® category 1 option for use after sorafenib (NEXAVAR) in Child-Pugh class A patients1*

Realize the potential of the systemic treatment plan

The survival benefits of STIVARGA demonstrated in RESORCE were in patients selected for good performance status and preserved liver function3-5

Monitor patients early and often throughout the course of treatment4

Planning for systemic therapy is possible for patients with unresectable HCC. Continue treatment with STIVARGA following NEXAVAR4